Systemic sclerosis & Raynaud's
Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis
Authors' conclusion
In this study, ICI therapy was well tolerated in patients with longstanding, sine or lcSSc. IrAE were common but generally manageable.
Study context
- Population
- Patients with systemic sclerosis (SSc) who received immune checkpoint inhibitor (ICI) therapy for cancer, Johns Hopkins Scleroderma Center Research Registry
- Participants
- 8 patients
- Outcome
- Worsening SSc activity or new irAEs
Methodological detailssingle-centre registry, chart review, prespecified definitions
- Single-centre registry
- Chart review
- Prespecified definitions
Main finding
As reported in the abstract
SSc disease activity after ICI therapy
- Worsening skin thickening and renal crisis in a patient early in diffuse cutaneous SSc (dcSSc) course
- 1
Observational data: associations, not effects.
Further findings
- No deaths due to immune related adverse events (irAEs)
- No deaths due to irAEs
Safety
irAEs (grade 2: diarrhea, mucositis and dermatitis; grade 3: pneumonitis; grade 4: nephritis)
- Patients with irAEs
- 3 (38 %)
- Total irAEs
- 5
Worsening SSc activity in early dcSSc
- Patients with worsening skin thickening and renal crisis
- 1
- Grade 4 nephritis patient developed scleroderma renal crisis and immune checkpoint related nephritis simultaneously
Original publication
Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis. Semin Arthritis Rheum. Published 4 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →